Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause...

Area of Science:

• Cardiology
• Interventional Cardiology
• Pharmacology

Background:

• Primary percutaneous coronary intervention (PCI) is a key treatment for ST-segment elevation myocardial infarction (STEMI).
• Antiplatelet therapy is crucial in managing STEMI patients undergoing primary PCI.
• Different in-catheter laboratory antiplatelet regimens may impact patient outcomes.

Purpose of the Study:

• To evaluate the impact of various in-catheter laboratory antiplatelet strategies on 1-year all-cause mortality.
• To compare the effectiveness of glycoprotein IIb/IIIa inhibitors and clopidogrel, alone or in combination, versus aspirin alone in primary PCI for STEMI.

Main Methods:

• A large, multicenter registry analysis of 7193 patients undergoing primary PCI for STEMI.
• Patients were categorized based on their in-catheter laboratory antiplatelet treatment: aspirin alone, glycoprotein IIb/IIIa inhibitors alone, clopidogrel alone, or combination therapy.
• Propensity-adjusted survival analysis was used to compare 1-year all-cause mortality rates among the groups.

Main Results:

• One-year mortality rates varied across groups: aspirin alone (10.4%), GP IIb/IIIa inhibitors alone (9.0%), clopidogrel alone (9.7%), and combination therapy (15.3%).
• Propensity-adjusted analysis revealed significantly lower mortality with GP IIb/IIIa inhibitors alone, clopidogrel alone, and combination therapy compared to aspirin alone.
• No significant survival benefit was observed for combination therapy over clopidogrel monotherapy.

Conclusions:

• In primary PCI for STEMI, using glycoprotein IIb/IIIa inhibitors and clopidogrel, individually or combined, is associated with reduced 1-year all-cause mortality compared to aspirin alone.
• Adding glycoprotein IIb/IIIa inhibitors to a 300 mg loading dose of clopidogrel did not provide further mortality reduction.